Biotie regains rights to develop PDE10 inhibitors for CNS disorders

Published October 18, 2010

Biotie regains rights to develop PDE10 inhibitors for CNS disorders
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 15 October 2010 at 12.15Biotie regains rights to develop PDE10 inhibitors for CNS disordersBiotie announced today that it will regain rights to compounds relating to PDE10 inhibition for the treatment …
Read more on wallstreet:online AG

Alkermes: FDA Widens Approved Use Of Vivitrol For Opioid Addiction
Alkermes: FDA Widens Approved Use Of Vivitrol For Opioid Addiction
Read more on FOX Business